Healis Therapeutics

Executive Summary

Healis Therapeutics is a private, preclinical-stage biotech company based in Cambridge, Massachusetts, pioneering a novel class of botulinum toxin-based neuromodulators for psychiatric disorders, with an initial focus on major depressive disorder (MDD). Founded in 2019, the company leverages proprietary intellectual property and strategic partnerships to advance its pipeline. The therapeutic approach represents a departure from traditional small-molecule antidepressants, potentially offering rapid-onset and sustained efficacy with a differentiated mechanism of action. Healis is currently preparing to enter Phase 1 clinical trials, marking a critical transition from preclinical development to human testing. The company operates in a high-need area, as MDD affects millions worldwide and existing treatments have limitations in efficacy, speed of onset, and tolerability. While still early-stage, Healis's innovative platform could address significant unmet medical needs if clinical proof-of-concept is established. The company's progress will depend on successful trial execution, regulatory interactions, and securing additional funding to support development through clinical milestones.

Upcoming Catalysts (preview)

• H1 2027Phase 1 clinical trial initiation for lead candidate in MDD65% success
• H2 2026Strategic partnership or licensing deal for neuromodulator platform40% success
• H2 2026Series A or B financing round to fund clinical development70% success